
Agenus (AGEN) Stock Forecast & Price Target
Agenus (AGEN) Analyst Ratings
Bulls say
Agenus Inc. presents a positive outlook due to its diverse pipeline of therapies aimed at activating the immune system, which includes antibody candidates botensilimab and balstilimab. The company's focus on compassionate use programs provides an additional revenue stream while generating real-world clinical evidence, particularly highlighted by promising efficacy in treating triple-negative and ER+ breast cancer through the NEOASIS trial. Furthermore, early favorable regulatory sentiment regarding bot/bal in metastatic colorectal cancer (MSS-CRC) suggests potential for additional growth and development opportunities in the near future.
Bears say
Agenus Inc's financial outlook is marred by several significant risks including the potential for emerging safety signals in its clinical or preclinical programs, which could negatively impact investor confidence. Moreover, there are concerns regarding the efficacy of its clinical programs potentially falling short of expectations, compounded by the possibility of increased competition from existing and emerging therapies in the market. Additionally, the company faces challenges related to regulatory approvals, ongoing financing requirements, and the need to secure robust intellectual property protection, all of which may hinder its growth prospects and overall market performance.
This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.
Agenus (AGEN) Analyst Forecast & Price Prediction
Start investing in Agenus (AGEN)
Order type
Buy in
Order amount
Est. shares
0 shares